<p>Actinium Pharmaceuticals，這家醫療行業公司，今天被華爾街分析師重新評估。來自 JonesTrading 的分析師 Justin Walsh 重申了對該股票的買入評級，並設定了 9.00 美元的目標價。</p>
<h3>享受 TipRanks Premium 50% 的折扣，放心投資</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的位置</li>
</ul>
<p>Justin Walsh 給予買入評級是基於多種因素的綜合考慮，主要集中在 Actinium Pharmaceuticals 的 ATNM-400 的有前景的臨牀前數據上。該資產在多種乳腺癌模型中顯示出顯著潛力，包括對常見治療如他莫昔芬和曲妥珠單抗耐藥的模型。這種在大實體腫瘤適應症中的廣泛抗腫瘤活性表明，ATNM-400 在進入臨牀試驗後可能提供可觀的發展機會。</p>
<p>此外，ATNM-400 在耐藥乳腺癌細胞中的結合和內化能力，以及在耐藥病例中與曲妥珠單抗聯合使用時的協同效應，進一步支持了其潛在療效。這些有希望的結果，加上公司穩健的財務狀況，促成了對 Actinium Pharmaceuticals 的樂觀前景和買入評級。</p>
<p>在 12 月 12 日發佈的另一份報告中，Maxim Group 也維持了對該股票的買入評級，目標價為 5.00 美元。</p>

Actinium制藥

<p>分析師 Justin Walsh 來自 JonesTrading 重申了對 Actinium Pharmaceuticals 的買入評級，目標價為 9.00 美元，原因是 ATNM-400 在乳腺癌模型中的有希望的臨牀前數據。該資產在耐藥病例中顯示出潛力，並與曲妥珠單抗具有協同效應。Maxim Group 也維持了買入評級，目標價為 5.00 美元，強調了公司的穩健財務狀況</p>

<p>Actinium Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Walsh from JonesTrading reiterated a Buy rating on the stock and has a $9.00 price target.</p>
<div class="lb-trans"><p>Actinium Pharmaceuticals，這家醫療行業公司，今天被華爾街分析師重新評估。來自 JonesTrading 的分析師 Justin Walsh 重申了對該股票的買入評級，並設定了 9.00 美元的目標價。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 的折扣，放心投資</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，幫助您做出更聰明、更精準的決策</li>
<li>通過最新的新聞和分析保持市場領先，使您的投資組合始終處於最大潛力的位置</li>
</ul>
</div><p>Justin Walsh has given his Buy rating due to a combination of factors, primarily focusing on the promising preclinical data of Actinium Pharmaceuticals’ ATNM-400. The asset has shown significant potential in various breast cancer models, including those resistant to common treatments like tamoxifen and trastuzumab. This broad anti-tumor activity in large solid tumor indications suggests that ATNM-400 could offer substantial development opportunities once it progresses to clinical trials.</p>
<div class="lb-trans"><p>Justin Walsh 給予買入評級是基於多種因素的綜合考慮，主要集中在 Actinium Pharmaceuticals 的 ATNM-400 的有前景的臨牀前數據上。該資產在多種乳腺癌模型中顯示出顯著潛力，包括對常見治療如他莫昔芬和曲妥珠單抗耐藥的模型。這種在大實體腫瘤適應症中的廣泛抗腫瘤活性表明，ATNM-400 在進入臨牀試驗後可能提供可觀的發展機會。</p>
</div><p>Moreover, ATNM-400’s ability to bind and internalize in resistant breast cancer cells, along with its synergistic effects when combined with trastuzumab in resistant cases, further supports its potential efficacy. These promising results, combined with the company’s solid financial position, contribute to the optimistic outlook and the Buy rating for Actinium Pharmaceuticals.</p>
<div class="lb-trans"><p>此外，ATNM-400 在耐藥乳腺癌細胞中的結合和內化能力，以及在耐藥病例中與曲妥珠單抗聯合使用時的協同效應，進一步支持了其潛在療效。這些有希望的結果，加上公司穩健的財務狀況，促成了對 Actinium Pharmaceuticals 的樂觀前景和買入評級。</p>
</div><p>In another report released on December 12, Maxim Group also maintained a Buy rating on the stock with a $5.00 price target.</p>
<div class="lb-trans"><p>在 12 月 12 日發佈的另一份報告中，Maxim Group 也維持了對該股票的買入評級，目標價為 5.00 美元。</p>
</div>

Actinium 製藥的 ATNM-400 展現出有前景的潛力，推動了買入評級